vs
Axsome Therapeutics, Inc.（AXSM）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Axsome Therapeutics, Inc.的季度营收约是BRC Group Holdings, Inc.的1.0倍（$196.0M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -14.6%，领先62.5%），Axsome Therapeutics, Inc.同比增速更快（65.0% vs -21.9%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（61.7% vs -15.4%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
AXSM vs RILY — 直观对比
营收规模更大
AXSM
是对方的1.0倍
$188.3M
营收增速更快
AXSM
高出86.9%
-21.9%
净利率更高
RILY
高出62.5%
-14.6%
两年增速更快
AXSM
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $196.0M | $188.3M |
| 净利润 | $-28.6M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | -13.8% | 32.3% |
| 净利率 | -14.6% | 47.9% |
| 营收同比 | 65.0% | -21.9% |
| 净利润同比 | 61.9% | 1710.8% |
| 每股收益（稀释后） | $-0.55 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMRILY
| Q4 25 | $196.0M | $188.3M | ||
| Q3 25 | $171.0M | $215.3M | ||
| Q2 25 | $150.0M | $188.2M | ||
| Q1 25 | $121.5M | $197.2M | ||
| Q4 24 | $118.8M | $241.0M | ||
| Q3 24 | $104.8M | $225.5M | ||
| Q2 24 | $87.2M | $256.0M | ||
| Q1 24 | $75.0M | $263.4M |
净利润AXSMRILY
| Q4 25 | $-28.6M | $90.3M | ||
| Q3 25 | $-47.2M | $91.1M | ||
| Q2 25 | $-48.0M | $139.5M | ||
| Q1 25 | $-59.4M | $-10.0M | ||
| Q4 24 | $-74.9M | $-5.6M | ||
| Q3 24 | $-64.6M | $-284.4M | ||
| Q2 24 | $-79.3M | $-433.6M | ||
| Q1 24 | $-68.4M | $-49.2M |
毛利率AXSMRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率AXSMRILY
| Q4 25 | -13.8% | 32.3% | ||
| Q3 25 | -27.0% | 30.4% | ||
| Q2 25 | -24.5% | 5.7% | ||
| Q1 25 | -46.9% | -31.2% | ||
| Q4 24 | -61.1% | -69.2% | ||
| Q3 24 | -59.8% | -36.4% | ||
| Q2 24 | -89.5% | -90.8% | ||
| Q1 24 | -89.7% | -6.1% |
净利率AXSMRILY
| Q4 25 | -14.6% | 47.9% | ||
| Q3 25 | -27.6% | 42.3% | ||
| Q2 25 | -32.0% | 74.1% | ||
| Q1 25 | -48.9% | -5.1% | ||
| Q4 24 | -63.1% | -2.3% | ||
| Q3 24 | -61.7% | -126.1% | ||
| Q2 24 | -91.0% | -169.4% | ||
| Q1 24 | -91.1% | -18.7% |
每股收益（稀释后）AXSMRILY
| Q4 25 | $-0.55 | $2.78 | ||
| Q3 25 | $-0.94 | $2.91 | ||
| Q2 25 | $-0.97 | $4.50 | ||
| Q1 25 | $-1.22 | $-0.39 | ||
| Q4 24 | $-1.54 | $-0.01 | ||
| Q3 24 | $-1.34 | $-9.39 | ||
| Q2 24 | $-1.67 | $-14.35 | ||
| Q1 24 | $-1.44 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $322.9M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $88.3M | $-171.5M |
| 总资产 | $689.8M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMRILY
| Q4 25 | $322.9M | $226.6M | ||
| Q3 25 | $325.3M | $184.2M | ||
| Q2 25 | $303.0M | $267.4M | ||
| Q1 25 | $300.9M | $138.3M | ||
| Q4 24 | $315.4M | $146.9M | ||
| Q3 24 | $327.3M | $159.2M | ||
| Q2 24 | $315.7M | $236.9M | ||
| Q1 24 | $331.4M | $190.7M |
总债务AXSMRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AXSMRILY
| Q4 25 | $88.3M | $-171.5M | ||
| Q3 25 | $73.7M | $-260.5M | ||
| Q2 25 | $73.1M | $-351.7M | ||
| Q1 25 | $53.2M | $-496.8M | ||
| Q4 24 | $57.0M | $-488.2M | ||
| Q3 24 | $92.9M | $-497.6M | ||
| Q2 24 | $102.9M | $-218.3M | ||
| Q1 24 | $144.0M | $228.4M |
总资产AXSMRILY
| Q4 25 | $689.8M | $1.7B | ||
| Q3 25 | $669.3M | $1.7B | ||
| Q2 25 | $639.8M | $1.5B | ||
| Q1 25 | $596.7M | $1.5B | ||
| Q4 24 | $568.5M | $1.8B | ||
| Q3 24 | $561.5M | $2.2B | ||
| Q2 24 | $548.2M | $3.2B | ||
| Q1 24 | $545.7M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-18.7M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $-18.7M | — |
| 自由现金流率自由现金流/营收 | -9.6% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-93.9M | — |
8季度趋势，按日历期对齐
经营现金流AXSMRILY
| Q4 25 | $-18.7M | $26.2M | ||
| Q3 25 | $1.0M | $-60.6M | ||
| Q2 25 | $-32.4M | $-25.6M | ||
| Q1 25 | $-43.4M | $184.0K | ||
| Q4 24 | $-26.2M | $-2.7M | ||
| Q3 24 | $-18.6M | $19.5M | ||
| Q2 24 | $-30.1M | $111.5M | ||
| Q1 24 | $-53.5M | $135.4M |
自由现金流AXSMRILY
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | — | ||
| Q2 25 | $-32.4M | — | ||
| Q1 25 | $-43.7M | — | ||
| Q4 24 | $-26.2M | — | ||
| Q3 24 | $-18.7M | — | ||
| Q2 24 | $-30.2M | — | ||
| Q1 24 | $-53.6M | — |
自由现金流率AXSMRILY
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | — | ||
| Q2 25 | -21.6% | — | ||
| Q1 25 | -36.0% | — | ||
| Q4 24 | -22.1% | — | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -34.6% | — | ||
| Q1 24 | -71.4% | — |
资本支出强度AXSMRILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
现金转化率AXSMRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
